Incidence and characteristics of pulmonary thromboembolism in Japan 2000

Internal Medicine

Volumn 42, Issue 11, 2003, Pages 1090-1094

  Kitamukai, Osamu ^a   Sakuma, Masahito ^a   Takahashi, Tohru ^a   Kagaya, Yutaka ^a   Watanabe, Jun ^a   Shirato, Kunio ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Incidence; Mortality; Pulmonary thromboembolism; Treatment

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; HEPARIN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; WARFARIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMOBILIZATION; INCIDENCE; INJURY; INTERMETHOD COMPARISON; JAPAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; QUESTIONNAIRE; REGISTRATION; RISK FACTOR; SURGERY; UNITED STATES;

EID: 0346252521     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.42.1090     Document Type: Article

References (24)

1. Kumasaka N, Sakuma M, Shirato K. Incidence of pulmonary thromboembolism in Japan. Jpn Circ J 63: 439-441, 1999.
2. Nakamura M, Okada O, Sakuma M, et al. Incidence and clinical characteristics of chronic pulmonary thromboembolism in Japan compared with acute pulmonary thromboembolism: results of a multicenter registry of the Japanese Society of Pulmonary Embolism Research. Circ J 66: 257-260, 2002.
3. Sakuma M, Konno Y, Shirato K. Increasing mortality from pulmonary embolism in Japan, 1951-2000. Circ J 66: 1144-1149, 2002.
4. Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis, American Heart Association. Circulation 93: 2212-2245, 1996.
5. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160: 809-815, 2000.
6. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 162: 1182-1189, 2002.
7. Sakuma M, Okada O, Nakamura M, et al. Recent developments in diagnostic imaging techniques and management for acute pulmonary embolism: multicenter registry by Japanese Society of Pulmonary Embolism Research. Intern Med 42: 470-476, 2003.
8. Lilienfeld DE, Chan E, Ehland J, Godbold JH, Landrigan PJ, Marsh G. Mortality from pulmonary embolism in the United States: 1962 to 1984. Chest 98: 1067-1072, 1990.
9. Sharma GV, Frisbie JH, Tow DE, Yalla SV, Khuri SF. Circadian and circannual rhythm of nonfatal pulmonary embolism. Am J Cardiol 87: 922-924, 2001.
10. Boulay F, Berthier F, Schoukroun G, Raybaut C, Gendreike Y, Blaive B. Seasonal variations in hospital admission for deep vein thrombosis and pulmonary embolism: analysis of discharge data. Br Med J 323: 601-602, 2001.
11. Sakuma M, Kumasaka N, Shirato K. Pulmonary thromboembolism: is the incidence accurate? Jpn Circ J 63: 825-827, 1999.
12. Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis 17: 259-270, 1975.
13. Research Committee on Serum Lipid Level. Current state of and recent trends in serum lipid levels in the general Japanese population: Research Committee on Serum Lipid Level Survey 1990 in Japan. J Atheroscler Thromb 2: 122-132, 1996.
14. Kawasaki T, Kambayashi J, Sakon M. Hyperlipidemia: a novel etiologic factor in deep vein thrombosis. Thromb Res 79: 147-151, 1995.
15. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 346: 1133-1134, 1995.
16. Seki T, Okayama H, Kumagai T, et al. Arg506Gln mutation of the coagulation factor V gene not detected in Japanese pulmonary thromboembolism. Heart Vessels 13: 195-198, 1998.
17. Ro A, Hara M, Takada A. The factor V Leiden mutation and the prothrombin G20210A mutation was not found in Japanese patients with pulmonary thromboembolism. Thromb Haemost 82: 1769, 1999.
18. Kunieda T, Naito M, Ookubo S, Yoshida T, Nakanishi N, Oobayashi Y. Clinical aspects and diagnosis of pulmonary thromboembolism. Nihon Kyobu Shikkan Gakkai Zasshi Jpn J Thorac Dis 26: 463-472, 1988.
19. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88: 3698-3703, 1996.
20. Margaglione M, Brancaccio V, De Lucia D, et al. Inherited thrombophilic risk factors and venous thromboembolism: distinct role in peripheral deep venous thrombosis and pulmonary embolism. Chest 118: 1405-1411, 2000.
21. Lilienfeld DE. Decreasing mortality from pulmonary embolism in the United States, 1979-1996. Int J Epidemiol 29: 465-469, 2000.
22. JerJes-Sanchez C, Ramirez-Rivera A, de Lourdes Garcia M, et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: A randomized controlled trial. J Thromb Thrombolysis 2: 227-229, 1995.
23. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W, Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 347: 1143-1150, 2002.
24. Bick RL, Haas SK. International consensus recommendations. Summary statement and additional suggested guidelines. European Consensus Conference, November 1991. American College of Chest Physicians consensus statement of 1995. International Consensus Statement, 1997. Med Clin North Am 82: 613-633, 1998.